Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS

Gene silencing with virally delivered shRNA represents a promising approach for treatment of inherited neurodegenerative disorders. In the present study we develop a subpial technique, which we show in adult animals successfully delivers adeno-associated virus (AAV) throughout the cervical, thoracic and lumbar spinal cord, as well as brain motor centers. One-time injection at cervical and lumbar levels just before disease onset in mice expressing a familial amyotrophic lateral sclerosis (ALS)-causing mutant SOD1 produces long-term suppression of motoneuron disease, including near-complete preservation of spinal α-motoneurons and muscle innervation. Treatment after disease onset potently blocks progression of disease and further α-motoneuron degeneration. A single subpial AAV9 injection in adult pigs or non-human primates using a newly designed device produces homogeneous delivery throughout the cervical spinal cord white and gray matter and brain motor centers. Thus, spinal subpial delivery in adult animals is highly effective for AAV-mediated gene delivery throughout the spinal cord and supraspinal motor centers. Injection of AAV–shRNA below the pial surface of the spinal cord prevents onset or ameliorates progression in a mouse model of ALS, and achieves widespread delivery to the spinal cord and brain motor centers in adult pigs and non-human primates.

[1]  L. Ferraiuolo,et al.  Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Robert H. Brown,et al.  Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates , 2015, Human gene therapy.

[3]  R. Desimone,et al.  A novel flexible cuff-like microelectrode for dual purpose, acute and chronic electrical interfacing with the mouse cervical vagus nerve , 2017, Journal of neural engineering.

[4]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[5]  J. Rothstein,et al.  Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Rivest,et al.  Sensorimotor and cognitive functions in a SOD1 G37R transgenic mouse model of amyotrophic lateral sclerosis , 2011, Behavioural Brain Research.

[7]  D Linden,et al.  Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. , 1998, Electroencephalography and clinical neurophysiology.

[8]  J. Julien,et al.  Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS , 2010, Journal of neurochemistry.

[9]  B. Monia,et al.  Antisense oligonucleotide therapy for neurodegenerative disease. , 2006, The Journal of clinical investigation.

[10]  E. Ahrens,et al.  Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs , 2016, Molecular therapy. Methods & clinical development.

[11]  Bin Wang,et al.  Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models , 2018, The Journal of clinical investigation.

[12]  M. Scadeng,et al.  Analysis of Dosing Regimen and Reproducibility of Intraspinal Grafting of Human Spinal Stem Cells in Immunosuppressed Minipigs , 2010, Cell transplantation.

[13]  D. Cleveland,et al.  Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond , 2009, The Journal of cell biology.

[14]  A. Miyanohara,et al.  Improved function of the failing rat heart by regulated expression of insulin-like growth factor I via intramuscular gene transfer. , 2012, Human gene therapy.

[15]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[16]  B. Fitzsimmons,et al.  In Vivo Gene Knockdown in Rat Dorsal Root Ganglia Mediated by Self-Complementary Adeno-Associated Virus Serotype 5 Following Intrathecal Delivery , 2012, PloS one.

[17]  Y. Hayashi,et al.  Cardiac sympathetic function in the patients with amyotrophic lateral sclerosis: analysis using cardiac [123I] MIBG scintigraphy , 2013, Journal of Neurology.

[18]  M. Chapleau,et al.  Methods of assessing vagus nerve activity and reflexes , 2011, Heart Failure Reviews.

[19]  Y. Itoyama,et al.  Disease progression of human SOD1 (G93A) transgenic ALS model rats , 2006, Journal of neuroscience research.

[20]  H. Hayashi,et al.  Amyotrophic lateral sclerosis with hypertensive attacks: Blood pressure changes in response to drug administration , 1996, Clinical Autonomic Research.

[21]  A. Higginbottom,et al.  Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS , 2018, Molecular therapy. Nucleic acids.

[22]  L. Goldstein,et al.  Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice , 2008, Proceedings of the National Academy of Sciences.

[23]  G. Kollias,et al.  Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.

[24]  E. Feldman,et al.  Human Neural Stem Cell Replacement Therapy for Amyotrophic Lateral Sclerosis by Spinal Transplantation , 2012, PloS one.

[25]  Y. Li,et al.  Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis , 2013, Nature Neuroscience.

[26]  Robert H. Brown,et al.  Adeno‐associated virus–delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model , 2016, Annals of neurology.

[27]  Jonathan P. Riley,et al.  Preclinical Safety Validation of a Stabilized Viral Vector Direct Injection Approach to the Cervical Spinal Cord , 2009, Clinical and translational science.

[28]  D. Cleveland,et al.  Enhancing Mitochondrial Calcium Buffering Capacity Reduces Aggregation of Misfolded SOD1 and Motor Neuron Cell Death without Extending Survival in Mouse Models of Inherited Amyotrophic Lateral Sclerosis , 2013, The Journal of Neuroscience.

[29]  A. Ferry,et al.  A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  L. Greensmith,et al.  Rodent models of amyotrophic lateral sclerosis. , 2013, Biochimica et biophysica acta.

[31]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[32]  Robert H. Brown,et al.  Silencing strategies for therapy of SOD1-mediated ALS , 2017, Neuroscience Letters.

[33]  Alberto Porta,et al.  Cardiovascular neural regulation is impaired in amyotrophic lateral sclerosis patients. A study by spectral and complexity analysis of cardiovascular oscillations , 2015, Physiological measurement.

[34]  S. McKeown,et al.  Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. , 2016, Gene.

[35]  D. Gutmann,et al.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis , 2008, Nature Neuroscience.

[36]  C. Brösamle,et al.  `Semifree-floating' treatment: a simple and fast method to process consecutive sections for immunohistochemistry and neuronal tracing , 1997, Journal of Neuroscience Methods.

[37]  S. Parikh,et al.  Autonomic etiology of heart block in amyotrophic lateral sclerosis: a case report , 2014, Journal of Medical Case Reports.